Roger Xie
Amministratore Delegato presso Beijing Pharmasciences Co. Ltd.
Profilo
Roger Xie founded China PharmaHub Corp.
in 2009, where he worked as Executive Vice President & Head-Global Development from 2009 to 2011.
Dr. Xie also currently works at Beijing Pharmasciences Co. Ltd., as Chief Executive Officer from 2009, Sumitomo Pharma America, Inc., as Senior Scientist, and UCB Research, Inc., as Senior Scientist.
Dr. Xie also formerly worked at Sirtris Pharmaceuticals, Inc., as Associate Director-Chemistry Operations in 2008, GSK Plc, as Associate Director-Chemistry Operations in 2009, China PharHub Corp., as Executive Vice President & Head-Global Development from 2009 to 2010, and Daiamed LLC, as Chief Scientist Officer in 2005.
Dr. Xie received his doctorate degree from Boston College and undergraduate degree from the University of Science & Technology of China.
Posizioni attive di Roger Xie
Società | Posizione | Inizio |
---|---|---|
Beijing Pharmasciences Co. Ltd. | Amministratore Delegato | 09/09/2010 |
UCB Research, Inc.
UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 09/09/2010 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Direttore Tecnico/Scientifico/R&S | 09/09/2010 |
Precedenti posizioni note di Roger Xie
Società | Posizione | Fine |
---|---|---|
CHINA PHARMAHUB CORP. | Fondatore | 06/01/2011 |
China PharHub Corp. /Old/
China PharHub Corp. /Old/ Financial ConglomeratesFinance China PharmaHub Corp. ('PharmaHub') is a global pharmaceutical HUB specializing in the identification, development and marketing of pharmaceutical and healthcare products that make a significant difference to patients and society. Their corporate headquarters are located in California, with offices locations in Boston and China. In China, they have developed productive alliances and partnerships that advance their capacity to develop innovative medicines at lower costs. PharmaHub is engaged in the commercialization of promising China preclinical and clinical stage novel compounds into the global pharmaceutical markets; as well as bringing U.S. preclinical and clinical stage novel compounds into the China pharmaceutical market. | Corporate Officer/Principal | 07/09/2010 |
GSK PLC | Corporate Officer/Principal | 01/03/2009 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/06/2008 |
Daiamed LLC | Direttore Tecnico/Scientifico/R&S | 01/05/2005 |
Formazione di Roger Xie
Boston College | Doctorate Degree |
University of Science & Technology of China | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
GSK PLC | Health Technology |
Aziende private | 7 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
China PharHub Corp. /Old/
China PharHub Corp. /Old/ Financial ConglomeratesFinance China PharmaHub Corp. ('PharmaHub') is a global pharmaceutical HUB specializing in the identification, development and marketing of pharmaceutical and healthcare products that make a significant difference to patients and society. Their corporate headquarters are located in California, with offices locations in Boston and China. In China, they have developed productive alliances and partnerships that advance their capacity to develop innovative medicines at lower costs. PharmaHub is engaged in the commercialization of promising China preclinical and clinical stage novel compounds into the global pharmaceutical markets; as well as bringing U.S. preclinical and clinical stage novel compounds into the China pharmaceutical market. | Finance |
UCB Research, Inc.
UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Commercial Services |
Daiamed LLC | |
China PharmaHub Corp.
China PharmaHub Corp. Pharmaceuticals: MajorHealth Technology China PharmaHub Corp. was a global pharmaceutical company. The firm was engaged in the identification, development, and marketing of pharmaceutical and healthcare products. The company was founded by Richard Lui, Monica Ding, and Roger Xie on July 9, 2009 and is headquartered in Diamond Bar, CA. | Health Technology |
Beijing Pharmasciences Co. Ltd. |
- Borsa valori
- Insiders
- Roger Xie